Global Meningococcal Vaccines Market is valued at USD 2.55 Billion in 2021 and expected to reach USD 4.87 Billion by 2028 with a CAGR of 9.7% over the forecast period.
Global Meningococcal Vaccines Market: Global Size, Trends, Competitive, Historical & Forecast Analysis, 2022-2028-Increasing prevalence of meningitis, rising vaccination drive in endemic regions and growing approval for meningococcal vaccines are major factors driving the growth of the Global Meningococcal Vaccines Market.
Meningococcal meningitis is an uncommon however possibly disturbing bacterial contamination that targets the brain. Meningococcal sickness is a condition or disease brought about by the bacterium Neisseria meningitides. It is one of the most deadly bacterial diseases that can be dangerous in a matter of hours. Meningococcal immunization vaccine to a biological substance directed for the avoidance of meningitis, which is an infectious contamination of the membranes encompassing the brain and the spinal cord. This disease is life threatening if not treated on time and most deadly bacterial infections. The disease can be of two types meningococcal meningitis in which there was infection of the protective membranes covering the brain and spinal cord and meningococcal septicemia in which bloodstream got infected. Meningococcal vaccines give protection against meningococcal disease. This serious disease can be prevented through meningococcal vaccines. The meningococcal vaccine has two types’ meningococcal conjugate or MenACWY vaccines Serogroup B meningococcal or MenB vaccines. Meningococcal vaccines are generally safe. The vaccination given to kids at age of 11 or 12 and booster dose is at the age of 16. The first meningococcal vaccine meningococcal polysaccharide vaccine was approved in 1978.
The Covid-19 pandemic has shown a negative impact on the growth of global meningococcal vaccines market. Due to the sudden spread corona virus and the increasing number of cases the government-imposed lockdown. The entire focus of medical and healthcare industry was shifted on Covid-vaccine development and in treating of Covid-patients.
Some of the key players for global meningococcal vaccines market are
The global meningococcal vaccines market is segmented on the basis of type, age group, vaccine stereotype, distribution channel and region & country level. On the basis of type, the meningococcal vaccines market is divided into polysaccharide vaccine, conjugate vaccine, and Serogroup B vaccine. On the basis of age group, the market can be classified into infants, children, adolescents & young adults, adults. On the basis of vaccine stereotype, the global meningococcal vaccines market is divided into MenB & Manic, MenACWY, MenC, MenA and MenAC. On the basis of distribution channel, the meningococcal vaccines market can be classified into hospital, online pharmacy, and retail pharmacy.
The regions covered in global meningococcal vaccines market report are North America, Europe, Asia-Pacific, Latin America and Rest of the World. On the basis of country level, the market of global meningococcal vaccines is subdivided into U.S., Mexico, Canada, U.K., France, Germany, Italy, China, India, Japan, South East Asia, Middle East Asia (UAE, Egypt, Saudi Arabia) GCC, Africa, etc.
On January 8th, 2022; CanSino Biologics Inc. announced that the National Medical Products Administration of China (""NMPA"") established approval for its ACYW135 Meningococcal Conjugate Vaccine (CRM197) (""MCV4"", trademark: Menhycia), making it the first of its sort to be approved in China. Utilizing CanSinoBIO's industry-driving manufactured biotechnology and formulation innovation platform, Menhycia covalently ties normal pathogenic meningococcal serogroups A, C, W135 and Y to the transporter protein CRM197. At present, Menhycia is the underlying vaccine item containing these four serogroups in China. Menhycia gives assurance to a wide range of age groups, including for kids matured 3 months to 3 years of age (47 months), by instigating solid T cell immune reactions and immunological memory for immunized youngsters.
On November 7th, 2021; a new vaccine was launched in New Zealand to protect infants, toddlers and teens against meningococcal disease. In New Zealand meningococcal B can beat at any age, but is most common in babies and kids under 5, followed by young people. An important and long-lasting meningococcal B epidemic among 1991 and 2007 resulted about 6128 cases and claimed 252 lives. In reaction to the outbreak, a short-term nationwide vaccination programme utilizing a tailor-made vaccine (MeNZB) was introduced between 2004 and 2008.
On November 25th, 2020; The European Commission (EC) approved MenQuadfi for the dynamic immunization of people aged of 12 months and older against obtrusive meningococcal infection brought about by Neisseria meningitides serogroups A, C, W and Y. This antibody has accessible worldwide to additionally extend protection to as many individuals as possible. The EC approval depended on information from in excess of 6,300 healthy people, matured 12 months and older, who all got a single dose of MenQuadfi. This data was from various clinical preliminaries, including seven Phase II and III preliminaries. In these investigations, MenQuadfi was contrasted with other authorized vaccines across all age groups.
One of the major factors driving the growth of global meningococcal vaccines market is increasing prevalence of meningitis. The disease is deadly and can be serious if untreated. The vaccination is the most effective and safe method of fight with the deadly meningococcal meningitis and it stops spread of the infection as well as prevents a person from acquiring the disease. Thus, rise in vaccination rates is in turn driving the market of meningococcal vaccines. For instance; according to the Centres for Disease Control and Prevention (CDC), over 1.2 million cases of bacterial meningitis are approximate to arise globally every year. In addition, another major factor supplementing the growth of global meningococcal vaccines market is growing vaccination drive in endemic regions. Meningococcal vaccines are common in sub- Saharan Africa. Thus, the vaccination programmes are started by government also boosting the growth of the market during the forecast period. For example; as per the news published on November 26th, 2021, urgent meningococcal vaccination programme launched by New Zealand government as the number of cases of group W meningococcal disease has doubled.
Furthermore, rising number of FDA approvals for meningococcal vaccines also drive the global meningococcal vaccines market. For instance; on April 24th, 2020, FDA approved meningococcal vaccine MenQuadfiTM. This increasing approval helping to drive the market over the forecast period. Additionally, government made meningococcal vaccination mandatory for travels and military man’s who are going to visit prone areas further fuelling the growth of the market. For example; ACIP recommended that travellers aged older than 2 months who visit or reside in parts of sub-Saharan Africa should receive vaccination with a MenACWY vaccine before travel.
However, stringent government restrictions for the approval of new vaccines may hamper the growth of the global meningococcal vaccine market. In spite of that, increasing research and development activities in the field of meningococcal vaccines and rising healthcare spending can provide various opportunities for the further growth of the global meningococcal vaccine market.
North America is expected to dominate the global meningococcal vaccines due to increasing cases of meningococcal infections, growing number of approval of vaccines and rising number awareness programmes by government for disease control in this region. For instance; according to the Centres for Disease Control and Prevention (CDC), there have been 371 cases of meningococcal disease in U.S in 2019. Thus, for treating these infections vaccine recommendation drives the growth of the market. In addition to that, rising number of vaccine approvals in U.S are further fostering the growth to the meningococcal vaccines market. For instance; in 2018, Food and Development Administration (FDA) granted breakthrough therapy designation for Pfizer Inc.’s Trumenba, a meningococcal group B (MenB) vaccine, for giving protection to kids below 10 years. Moreover, increasing government initiatives are further driving the growth of the market. For example; on August 12th, 2021, National Foundation for Infectious Diseases (NFID) and DoSomething.org launched new program in that they will aware young people about necessity of vaccination and its benefits young people about meningococcal disease prevention.
Europe is second dominating region in the global meningococcal market due to the rising awareness about meningococcal disease, growing government efforts and increasing meningococcal infections in this region. For instance; according to the Public Health of England (PHE); there were 4 confirmed cases of MenY during quarter of 2021 and in January and March 2021, there were 6 cases of IMD in children’s who were smaller than 5 years. In addition, the GlaxoSmithKline’s vaccine GSK’s meningitis B vaccine Bexsero received Breakthrough Therapy Designation from U.S. FDA for prevention of invasive meningococcal disease in children 2-10 years of age fuelling the growth of the market.
Asia Pacific is expected to witness significant growth in global meningococcal vaccines market due to increasing prevalence of meningitis and rising government initiatives in this region. For example; according to the National Immunization programs (NIPs), Indian government to vaccination of newborns, children and adults against meningococcal disease will continue to create profitable growth in Asia Pacific region.
|Historical data||2015 - 2020|
|Forecast Period||2021 - 2028|
|Market Size in 2021:||USD 2.55 Billion|
|Base year considered||2020|
|Forecast Period CAGR %:||
|Market Size Expected in 2028:||USD 4.87 Billion|
|Tables, Charts & Figures:||175|
|Meningococcal Vaccine Manufacturers||Sanofi Pasteur, Merck, GlaxoSmithKline, Human Biologicals Institute, LG Life Sciences, Kaketsuke, Dynavax Technologies, Janssen Pharmaceuticals, and others.|
|Segments Covered||By Type, By Age Group, By Vaccine Stereotype, By Distribution Channel|
|Regional Analysis||North America, U.S., Mexico, Canada, Europe, UK, France, Germany, Italy, Asia Pacific, China, Japan, India, Southeast Asia, South America, Brazil, Argentina, Columbia, The|